Immune modulation of i.v. immunoglobulin in women with reproductive failure.

Published in: Reproductive medicine and biology (2018)

The authors recommend IVIg therapy in patients with RF with aberrant cellular immunologic parameters, including a high natural killer cell proportion and its cytotoxicity or elevated T helper 1 to T helper 2 ratio, based on each clinic's cut-off values. Further clinical studies about the safety of IVIg in the fetus and its efficacy in other immunologic abnormalities of RF are needed.

Keyphrases

regulatory t cells
dendritic cells
cell therapy
single cell
primary care
immune response
nk cells